KEZAR LIFE SCIENCES INC

KEZAR LIFE SCIENCES INC (KZR)

$2.78

[object Object]

([object Object]%)

Market is closed - opens 7 PM, 02 Jun 2023

Insights on KEZAR LIFE SCIENCES INC

  • Vs SGEN

    In the last 1 year, Seagen Inc has given 45.9% return, outperforming this stock by 88.7%

  • Vs MRNA

    In the last 3 years, Moderna Inc has given 23.1% return, outperforming this stock by 66.2%

Performance

  • $2.78
    $2.89
    $2.78
    downward going graph

    0.0%

    Downside

    Day's Volatility :3.81%

    Upside

    3.81%

    downward going graph
  • $2.25
    $11.02
    $2.78
    downward going graph

    19.06%

    Downside

    52 Weeks Volatility :79.58%

    Upside

    74.77%

    downward going graph

Returns

PeriodKEZAR LIFE SCIENCES INCSector (Health Care)Index (Russel 2000)
3 Months
-50.49%
0.7%
-6.8%
6 Months
-62.83%
-8.3%
-6.0%
1 Year
-42.8%
-1.9%
-4.6%
3 Years
-43.15%
25.3%
25.9%

Highlights

Market Capitalization
206.4M
Book Value
$3.57
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-1.08
Wall Street Target Price
15.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-18.61%
Return On Equity TTM
-30.7%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-78.9M
Diluted Eps TTM
-1.08
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.3
EPS Estimate Next Year
-1.35
EPS Estimate Current Quarter
-0.29
EPS Estimate Next Quarter
-0.3

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for KEZAR LIFE SCIENCES INC(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
9
Hold
2
2
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 457.55%

Current $2.78
Target $15.50

Technicals Summary

Sell

Neutral

Buy

KEZAR LIFE SCIENCES INC is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
KEZAR LIFE SCIENCES INC
KEZAR LIFE SCIENCES INC
11.65%
-62.83%
-42.8%
-43.15%
-84.34%
Moderna, Inc.
Moderna, Inc.
-4.27%
-29.63%
-10.94%
105.39%
586.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-8.82%
-3.37%
11.63%
22.7%
139.69%
Seagen, Inc.
Seagen, Inc.
-1.74%
61.71%
45.87%
23.07%
217.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.21%
0.88%
20.1%
12.88%
112.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
KEZAR LIFE SCIENCES INC
KEZAR LIFE SCIENCES INC
NA
NA
NA
-1.3
-0.31
-0.19
0.0
3.57
Moderna, Inc.
Moderna, Inc.
11.46
11.46
0.0
-1.9
0.27
0.12
0.0
49.12
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
19.72
19.72
9.01
41.59
0.19
0.1
0.0
219.38
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-2.88
-0.23
-0.12
0.0
14.54
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.15
26.15
0.41
14.62
0.26
0.17
0.0
56.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
KEZAR LIFE SCIENCES INC
KEZAR LIFE SCIENCES INC
Buy
$206.4M
-84.34%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$49.1B
586.61%
11.46
31.77%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$79.5B
139.69%
19.72
33.81%
Seagen, Inc.
Seagen, Inc.
Hold
$36.7B
217.59%
NA
-31.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$83.8B
112.8%
26.15
35.4%

Institutional Holdings

  • Avidity Partners Management LP

    9.01%
  • Orbimed Advisors, LLC

    6.33%
  • BlackRock Inc

    5.85%
  • Suvretta Capital Management, LLC

    4.84%
  • State Street Corporation

    4.48%
  • Vanguard Group Inc

    4.16%

Corporate Announcements

  • KEZAR LIFE SCIENCES INC Earnings

    KEZAR LIFE SCIENCES INC’s price-to-earnings ratio stands at None

    Read More

Company Information

Based in South San Francisco, Kezar Life Sciences is combining courage, conviction and cutting-edge science to develop breakthrough treatments for immune-mediated and oncologic disorders. The company is pioneering first-in-class, small-molecule therapies that harness master regulators of cellular function and inhibit multiple drivers of disease via a single target. KZR-616, a first-in-class selective immunoproteasome inhibitor, is being evaluated in severe and underserved autoimmune diseases. Additionally, KZR-261, the first clinical candidate for the treatment of cancer from the company's protein secretion program targeting the Sec61 translocon, is undergoing IND-enabling activities.

Organization
KEZAR LIFE SCIENCES INC
Employees
84
CEO
Mr. John Franklin Fowler
Industry
Health Technology

FAQs